tbuckley/cabot-search huggingface dataset:
TCT-185 Effect of IVL in Varying Calcium Morphologies: A Prospective Study With Optical Coherence Tomography Analysis
Authors: Angela McInerney, Fernando Alfonso, Alejandro Travieso, David del Val, Enrico Cerrato, Salvatore Brugaletta, Manel Sabate, Juan Garcia de Lara, Marcelo Jiménez Kockar, Alejandro Diego Nieto, Alfonso Jurado-Roman, Pedro L. Cepas-Guillen, Jose de la Torre Hernandez, Eduardo Pinar Bermudez, Hector Cubero-Gallego, Beatriz Vaquerizo, Armando Perez de Prado, Victor Alfonso Jimenez Diaz, Ignacio Amat-Santos, Ferdinando Varbella, Pilar Jimenez-Quevedo, Gabriela Tirado-Conte, Fernando Macaya, Luis Nombela-Franco, Antonio Fernandez-Ortiz, Javier Escaned, Nieves Gonzalo
Journal: Journal of the American College of Cardiology (2022)
1403P Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial
Authors: R.H. Jones, D.J. Pinato, A. Joshua, M.D. Forster, C. Morton, K. Aboud, J.J. Liu, C. Fulgenzi, J. Kefas, S. Edmondson, N.J. Main, J.R.A. Paull, J.K. Fairley, J. Spicer
Journal: Annals of Oncology (2022)
LBA38 BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours
Authors: A. Mackensen, J.B.A.G. Haanen, C. Koenecke, W. Alsdorf, E. Wagner-Drouet, D. Heudobler, P. Borchmann, C. Bokemeyer, S. Klobuch, E. Smit, F. Müller, A. Desuki, F. Lüke, E. Wiegert, C. Flemmig, C. Schulz-Eying, B. Rengstl, L. Preussner, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2022)
1626P Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials
Authors: L. Marandino, F. Trastu, E. Ghisoni, P. Lombardi, A. Mariniello, M.L. Reale, G. Aimar, M. Audisio, M. Bungaro, A. Caglio, R. Di Liello, T. Gamba, P. Gargiulo, C. Paratore, A. Rossi, V. Tuninetti, F. Turco, F. Perrone, M. Di Maio
Journal: Annals of Oncology (2022)
1397P Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
Authors: M. Linch, G. Liu, S.J. Crabb, T.M. Beer, E. Heath, M. Gordon, J.S. de Bono, H.I. Pashova, I.C. Tudor, J.M. Custodio, G. Mann, M.J. Morris
Journal: Annals of Oncology (2022)
LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Authors: M. Chalabi, Y.L. Verschoor, J. van den Berg, K. Sikorska, G. Beets, A.V. Lent, M.C. Grootscholten, A. Aalbers, N. Buller, H. Marsman, E. Hendriks, P.W.A. Burger, T. Aukema, S. Oosterling, R. Beets-Tan, T.N. Schumacher, M. van Leerdam, E.E. Voest, J.B.A.G. Haanen
Journal: Annals of Oncology (2022)
1401P Quality of life across three countries using a large-scale, fully digital survey of patients with prostate cancer
Authors: J. O'Sullivan, B.D. Gonzalez, L.M. Gudenkauf, R. Lehmann, S. Allen, C. Ernst-Guenther, H. Wolinsky, A. Poschenrieder, O. Mirante, A.K. Morgans
Journal: Annals of Oncology (2022)
1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention
Authors: T. Scheinberg, M. Fitzpatrick, H-M. Lin, A.A. Azad, P. Bonnitcha, A.G. Davies, G. Heller, K. Huynh, B. Mak, K. Mahon, P. Meikle, D. Sullivan, L.G. Horvath
Journal: Annals of Oncology (2022)
1395P Real-world association between bone targeted agents and palliative bone radiation in prostate cancer decedents: A province-wide study
Authors: W.J. Phillips, A. Jooya, R. Mahdavi, J. Leigh, K. Tawagi, C. Webber, C. Milani, S.C. Morgan, R. MacRae, J-M. Bourque, P. Tanuseputro, M. Ong
Journal: Annals of Oncology (2022)
1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: F. Saad, A.J. Armstrong, A. Thiery-Vuillemin, M. Oya, N.D. Shore, G. Procopio, C. Arslan, N. Mehra, F. Parnis, E. Brown, F. Constans Schlurmann, J.Y. Joung, M. Sugimoto, O. Sartor, Y-Z. Liu, C.H. Poehlein, C. Desai, P.M.D. Del Rosario, N. Clarke
Journal: Annals of Oncology (2022)
1402P Initial results of a cohort of advanced prostate cancer patients in a phase Ia study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody
Authors: I. Medic, S. Gulati, H-J. Lenz, D. Mahalingam, J. Thomas, J. Luo, J. Zha, A. DePaoli, C. Tran-Muchowski, C. Tseng, H. Lieu
Journal: Annals of Oncology (2022)
1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)
Authors: R.A. Madan, R. Donahue, Y-T. Tsai, F. Karzai, S. Gandhy, M. Bilusic, P. Arlen, M. Theoret, J. Marte, L. Cordes, A. Couvillon, A. Hankin, M. Williams, S. McMahon, W.D. Figg, W. Dahut, J. Schlom, J. Gulley
Journal: Annals of Oncology (2022)
1414P Treatment efficacy and safety of 177Lu-PSMA radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer
Authors: R.L. Tauber, M. Retz, K. Knorr, C. D’Alessandria, S. Grigorascu, K. Hansen, H-J. Wester, J. Gschwend, W. Weber, M. Eiber, T. Langbein
Journal: Annals of Oncology (2022)
LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases
Authors: E. Romano, L. Castelo-Branco, Z. Tsourti, E. de Azambuja, S. Gennatas, J. Oliveira, J. Rogado, M. Sekacheva, S. Susnjar, D. Vinal Lozano, R. Lee, S.M. Khallaf, G. Dimopoulou, S. Pradervand, D. Arnold, K.J. Harrington, O.A. Michielin, U. Dafni, G. Pentheroudakis, S. Peters
Journal: Annals of Oncology (2022)
1408P Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa)
Authors: M.L.K. Chua, A. Sim, A. Hakansson, E. Ong, K.P. Low, C. Tan, J. Tan, A.S.Y. Lau, J. Tuan, T.W.K. Tan, M.L.C. Wang, J.P.S. Yeong, M.C.S. Tan, L.S. Lee, R. Kanesvaran, K.J. Tay, S. Liu, L.Y. Khor, E. Davicioni
Journal: Annals of Oncology (2022)
1411P Development and validation of a novel six-gene signature to accurately risk stratify men with early-stage prostate cancer to aid in treatment decision making
Authors: A. Krzyzanowska, S. Barron, T. Loughman, D.F. Higgins, K.M. Sheehan, A. Chan-Ju Wang, B. Fender, L.M. McGuire, A. O'Neill, J. Fay, T. O'Grady, D. O'Leary, A. Bjartell, R.W.G. Watson, W.M. Gallagher
Journal: Annals of Oncology (2022)
LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
Authors: N.A. Dasari, S. Lonardi, R. Garcia-Carbonero, M.E. Elez Fernandez, T. Yoshino, A.F. Sobrero, J.C. Yao, P. García-Alfonso, J. Kocsis, A. Cubillo Gracian, A. Sartore Bianchi, T. Satoh, V. Randrian, J. Tomasek, G. Chong, Z. Yang, W. Schelman, M. Kania, J. Tabernero, C. Eng
Journal: Annals of Oncology (2022)
1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)
Authors: C.F. Stockem, B.W.G. van Rhijn, T. Boellaard, M.L. van Montfoort, S. Balduzzi, J. Boormans, M. Franckena, R. Meijer, J. Noteboom, D. Robbrecht, B.B. Suelmann, E. Schaake, M.S. van der Heijden
Journal: Annals of Oncology (2022)
1200TiP Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Authors: H.S. Orer, G. Nomak, B. Oksuzoglu, R. Senturk, Y. Eralp, F. Yumuk, H. Nomak, R. Sanyal
Journal: Annals of Oncology (2022)
1410P Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
Authors: S. Gupta, A. Hong, N.N. El-Chaar, C. Young, K. Ramaswamy, B. Xie, S. Bunner, B. Diessner, U. Swami
Journal: Annals of Oncology (2022)
1201TiP MINOVA: A phase II, open-label, single arm, multicenter, exploratory study with osimertinib plus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations
Authors: M. Huang, Y. Gong, Y. Liu, Y. Zhang, Y. Lu
Journal: Annals of Oncology (2022)
1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH
Authors: A.R. Hansen, S. Probst, R.F. Tutrone, M.M. Osman, E.S. Delpassand, L.T. Nordquist, B.L. Viglianti, J.M. Michalski, J-M. Beauregard, O.K. Oz, K. Courtney, J. Jensen, W. Wu, N. Fleshner, O. Sartor, K.N. Chi, S.T. Tagawa
Journal: Annals of Oncology (2022)
1405P Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)
Authors: Z. Guillaume, A. Bayle, C. Pobel, L. Lacroix, D. Vasseur, L. Albiges, E. Colomba, R. Flippot, N. Naoun, A. Patrikidou, V. Goldschmidt, P. Vuagnat, C. Massard, S. Ponce, K. Fizazi, Y. Loriot, C. Baldini, A. Italiano, A. Bernard-Tessier
Journal: Annals of Oncology (2022)
1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE
Authors: Á.M. Haran, Y. Jain, T. Hambrock, L.R. Murphy, A. Cook, L.C. Brown, A.P. Hoyle, A. Sachdeva, S.A. Ali, C.L. Amos, M.R. Sydes, G. Attard, M.K. Parmar, N.D. James, N.W. Clarke
Journal: Annals of Oncology (2022)
1399P Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: N. Tripathi, B. Chigarira, N. Sayegh, V. Mathew Thomas, S. Adidam Kumar, D. Goel, C. Tandar, T.R. Mcfarland, R. Nussenzveig, D. Sirohi, U. Swami, B.L. Maughan, N. Agarwal
Journal: Annals of Oncology (2022)
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Authors: I.L. Ray-Coquard, A. Leary, S. Pignata, C. Cropet, A.J. Gonzalez Martin, G. Bogner, H. Yoshida, I.B. Vergote, N. Colombo, J. Maenpaa, F. Selle, B. Schmalfeldt, G. Scambia, E.M. Guerra Alia, C. Lefeuvre-Plesse, A. Belau, A. Lortholary, M. Gropp-Meier, E. Pujade-Lauraine, P. Harter
Journal: Annals of Oncology (2022)
LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
Authors: M.P. Goetz, P. Plourde, D.G. Stover, N. Bagegni, G.A. Vidal, A. Brufsky, H.S. Rugo, D.J. Portman, E. Gal-Yam
Journal: Annals of Oncology (2022)
1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
Authors: D.P. Petrylak, A.A. Azad, R.Z. Szmulewitz, T. Iguchi, N.D. Shore, J. Holzbeierlein, B. Alekseev, N.N. El-Chaar, B. Rosbrook, J. Ma, F. Zohren, G.P. Haas, A. Stenzl, A.J. Armstrong
Journal: Annals of Oncology (2022)
1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Authors: E. Lim, J. Reeves, S. Gandhi, D.R. Spigel, E. Arrowsmith, D.J. George, J. Karlix, G. Pouliot, M. Hattersley, E. Gangl, G. James, J. Thompson, D. Russell, B. Patel, R. Kumar, G.S. Falchook
Journal: Annals of Oncology (2022)
A Text-Book of the Practice of Medicine. For Students and Practitioners.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vestibulotoxicity with gentamicin
Authors: Karina Ferreira, Suzanne Forbes, Diego Kaski
Journal: BMJ (2022)

### What you need to know A patient reports feeling unsteady while walking. This has come up suddenly. He had a renal stent inserted for calculi removal two days previously, for which he received intravenous gentamicin as prophylaxis. He also reports wobbly vision on head movement, which resolves with his head held still. Neurological examination reveals severe gait imbalance, with the patient requiring support for walking even short distances. He is diagnosed with gentamicin related vestibulotoxicity and started on vestibular rehabilitation. Aminoglycoside antibiotics are implicated in functional impairment and/or cellular damage to the vestibular system as an adverse reaction (box 1).4 Gentamicin is the most frequently used aminoglycoside antibiotic in adults.56 As with other aminoglycosides such as streptomycin and tobramycin, gentamicin related vestibulotoxicity is typically bilateral due to systemic administration. The damage can be permanent. Early diagnosis can help initiate measures to improve balance. This article focuses on gentamicin related vestibulotoxicity in adults. Symptoms and the indications for gentamicin use, dosing, and monitoring can differ in children. Box 1 ### Safety warnings for gentamicin and aminoglycosidesRETURN TO TEXT
TCT-207 Intravascular Lithotripsy for Calcified Peripheral Artery Disease (PAD) in Female vs Male Patients: Sex-Specific Analysis From the Disrupt PAD III Observational Study
Authors: Sameer Nagpal, Katharine McGinigle, Sarang Mangalmurti, George Adams, Nicolas Shammas, Peter Soukas, Barry Bertolet, Alexandra Lansky
Journal: Journal of the American College of Cardiology (2022)
TCT-180 Efficacy and Safety of Rotational Atherectomy in Patients With Non ST Elevation - Acute Coronary Syndromes
Authors: Ali Farooq, Anoop Koshy, Gennaro Giustino, Amit Hooda, Htoo Kyaw, Parasuram Krishnamoorthy, Joseph Sweeny, Roxana Mehran, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2022)
TCT-178 Shockwave Intravascular Lithotripsy (IVL) for Calcified Coronary Lesions; A Real World Multicentre European Study With Long Term Follow Up
Authors: Waseem Raja, Luca Testa, Prashanth Raju, Vinoda Sharma, Ahmed Hailan, Angelo Mastrangelo, Ajay Sundara Raman, Sandeep Basavarajaiah
Journal: Journal of the American College of Cardiology (2022)
TCT-194 Impact of Schizophrenia on In-Hospital Outcomes Among Patients Undergoing Percutaneous Coronary Interventions: A National Inpatient Sample Analysis
Authors: Tushar Mishra, Dhruvil Patel, Irfan Shafi, Woosun Kang, John Dayco, Ahmed Yassin, John Dawdy, Adel Elmoghrabi, Ayman Soubani, M. Chadi Alraies, Nasser Lakkis
Journal: Journal of the American College of Cardiology (2022)
TCT-201 Linkage of Diabetic Status With Thrombogenic Indices and Its Prognostic Implication in Patients Undergoing Percutaneous Coronary Intervention
Authors: Jong-Hwa Ahn, Jin-Sin Koh, Yongwhi Park, Seok-Jae Hwang, Moonki Jung, Sang-Wook Kim, Jin-Yong Hwang, Young-Hoon Jeong, Sungsoo Cho
Journal: Journal of the American College of Cardiology (2022)
TCT-197 Comparing In-Hospital Outcomes of Percutaneous Coronary Intervention in Non-ST Segment Elevation Myocardial Infarction and Prior Coronary Artery Bypass Graft With and Without Type II Diabetes
Authors: Suchith Shetty, Antony Anandaraj, Wilbert Aronow, Aaqib Malik
Journal: Journal of the American College of Cardiology (2022)
Hard-core Smokers
Authors: Joseph R. DiFranza
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Pierce et al<sup>1</sup>postulate that "hard-core smokers" may slow down the rate of decline in the prevalence of smoking as they come to represent a greater proportion of the smoking population. However, the authors do not identify these hard-core smokers except to imply that they are not the heavy smokers, because the proportion of heavy smokers in the population has not increased. If there is a group of hard-core smokers, it must be the alcoholics. Alcoholics have quit ratios (the proportion of "ever smokers" who are former smokers) only one seventh that of nonalcoholics (7% vs 49%).<sup>2</sup> The projections of Pierce et al can be combined with recent data comparing the quit ratios of alcoholics and nonalcoholics to illustrate how the prevalence of alcoholism among smokers will increase in coming years.<sup>2,3</sup> The projected rate of decline in the prevalence of smoking in the general
Coronary-Prone Individuals (Type A Behavior Pattern)
Authors: Meyer Friedman
Journal: JAMA (1971)

The average resting and after arginine hydrochloride infusion plasma growth hormone concentrations of relatively coronary-prone subjects (persons with type A behavior pattern) were found to be significantly lower than those of relatively coronary-resistant individuals (subjects with type B behavior pattern). This difference does not appear to be a fixed one, but is related to the intensity of the behavior pattern present at the time of study.
The Physician's Visiting List.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA A 1
Authors: Thomas Francis, Jonas E. Salk, Harold E. Pearson, Philip N. Brown
Journal: Journal of Clinical Investigation (1945)

In December 1942, rather extensive studies, which will be reported separately, were begun for the purpose of determining the value of subcu- taneous vaccination with a vaccine of inactivated influenza viruses, Types A and B, against the epidemic form of influenza.The anticipated out- break of this disease did not occur but the oppor- tunity to test the resistance of certain of the vac- cinated individuals to induced infection presented itself.This was done by inducing infection with strains of virus maintained under laboratory con- ditions.Other investigators (1) had previously reported that, by the use of such a procedure, vac- cine containing inactivated Type A influenza virus, given subcutaneously, was demonstrated to have protected children against experimental infection.A preliminary report of the clinical results has already been made (2).The present report is intended to present the details of the evidence for the protective effect of vaccination against induced influenza A, including the laboratory investigations which constituted an important phase of the study. MATERIALS AND METHODSVaccine.The vaccine employed was prepared by the medical research division of Sharp & Dohmes according to specifications
The 1940 Year Book of General Medicine
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals
Authors: J. Rodríguez-Baño, M.D. López-Prieto, M.M. Portillo, P. Retamar, C. Natera, E. Nuño, M. Herrero, A. del Arco, A. Muñoz, F. Téllez, M. Torres-Tortosa, A. Martín-Aspas, A. Arroyo, A. Ruiz, R. Moya, J.E. Corzo, L. León, J.A. Pérez-López
Journal: Clinical Microbiology and Infection (2010)